Abstract
The use of left ventricular assist devices (LVADs) is increasingly more common as the availability of donor organs in relation to failing hearts is outstandingly limited. Infections are the most common complications in LVAD recipients, particularly those caused by Staphylococcus spp. Refractory LVAD-related infections are not uncommon as achieving adequate source control is often not feasible before heart transplantation. Evidence suggest that cefazolin plus ertapenem is effective in refractory methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, but this approach has not been described in LVAD recipients. In this article, we report two cases of refractory MSSA bacteremia in LVAD recipients that were successfully treated with salvage therapy with cefazolin plus ertapenem and subsequent heart transplantation. This treatment strategy should be considered in patients with refractory LVAD-associated infection due to MSSA that are not responding to standard treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 4786-4788 |
| Number of pages | 3 |
| Journal | Journal of Cardiac Surgery |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2021 |
Bibliographical note
Publisher Copyright:© 2021 Wiley Periodicals LLC
Keywords
- LVAD infection
- Staphylococcus aureus
- bacteremia
- cefazolin
- ertapenem
- salvage therapy
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Cefazolin plus ertapenem and heart transplantation as salvage therapy for refractory LVAD infection due to methicillin-susceptible Staphylococcus aureus: A case series'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver